| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Graphite Bio, Inc. | Director | Stock Option (right to buy) | 20,000 | 19 Jul 2023 | Direct | ||
| Jounce Therapeutics, Inc. | Director | Common Stock | 0 | $1.85 | 03 May 2023 | Direct | |
| Jounce Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 0 | 03 May 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LENZ | Graphite Bio, Inc. | 19 Jul 2023 | 1 | $0 | 4 | Director | 21 Jul 2023, 17:10 |
| /report/000164045523000111-karsen-perry-a-2023-05-03 | Jounce Therapeutics, Inc. | 03 May 2023 | 8 | $0 | 4 | Director | 04 May 2023, 07:44 |
| /report/000164045522000073-karsen-perry-a-2022-06-24 | Jounce Therapeutics, Inc. | 24 Jun 2022 | 1 | $0 | 4 | Director | 28 Jun 2022, 21:07 |
| LENZ | Graphite Bio, Inc. | 21 Jun 2022 | 1 | $0 | 4 | Director | 22 Jun 2022, 17:38 |
| LENZ | Graphite Bio, Inc. | 24 Jun 2021 | 0 | $0 | 3 | Director | 24 Jun 2021, 21:14 |
| /report/000164045521000108-karsen-perry-a-2021-06-18 | Jounce Therapeutics, Inc. | 18 Jun 2021 | 1 | $0 | 4 | Director | 22 Jun 2021, 16:34 |
| LENZ | Graphite Bio, Inc. | 13 Jan 2021 | 5 | +$100,001 | 4 | Director | 01 Jul 2021, 19:00 |